GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 2010-2014  (217)
Material
Language
Years
  • 2010-2014  (217)
Year
  • 1
    Online Resource
    Online Resource
    Japan Oil Chemists' Society ; 2014
    In:  Journal of Oleo Science Vol. 63, No. 1 ( 2014), p. 25-30
    In: Journal of Oleo Science, Japan Oil Chemists' Society, Vol. 63, No. 1 ( 2014), p. 25-30
    Type of Medium: Online Resource
    ISSN: 1345-8957 , 1347-3352
    Language: English
    Publisher: Japan Oil Chemists' Society
    Publication Date: 2014
    detail.hit.zdb_id: 2218264-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Leukemia Research, Elsevier BV, Vol. 37, No. 9 ( 2013-9), p. 1046-1051
    Type of Medium: Online Resource
    ISSN: 0145-2126
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2013
    detail.hit.zdb_id: 2008028-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 1938-1938
    Abstract: Abstract 1938 Background: Toll-like receptors (TLRs) are transmembrane proteins on the surface of immune cells that detect conserved molecular motifs known as “microbe-associated molecular patterns” from a variety of organisms. They interact with several adapter proteins to activate transcription factors, leading to the production of inflammatory cytokines and the activation of adaptive immunity. Current evidence suggests that common polymorphisms in TLR genes have been associated with the susceptibility to autoimmune disease and several infections, their association with outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has yet to be explored. Methods: We unselectively included all patients undergoing allo-HSCT in our Bone Marrow Transplantation Center between January 2001 and March 2009 if donor and patient DNA were available. All the patients and their donors were from a homogeneous genetic background. We analyzed 10 single nucleotide polymorphisms (SNPs) in the TLR1gene (rs4833095 C/T, rs5743565 A/G), TLR2gene (rs11938228 A/C, rs3804099 C/T), TLR3 gene (rs3775291 A/G, rs3775296 G/T), TLR8gene (rs3764880 A/G, rs2159377 C/T) and TLR9 gene (rs352139 G/A, rs352140 C/T) in 2 independent cohorts. The initial cohort consisted of 138 pairs of patients and their unrelated donors (URDs). The second cohort consisted of 102 pairs of patients and their HLA-identical sibling donors. Results: (1) We found that two SNPs in donor side, TLR9 +1174 G/A (rs352139) and TLR9 +1635 C/T (rs352140), influenced the risk of aGVHD. The association was particularly strong in the URD transplantation cohort. Multivariate analysis confirmed that an unrelated donor with the TLR9 +1174 variant allele (A allele) was an independent risk factor for aGVHD (P= 0.009, RR= 3.123). In contrast, an unrelated donor with the TLR9 +1635 variant genotype (TT) was protective (P= 0.067, RR= 3.457). The same effect was observed in the sibling transplantation cohort, although the incidence of clinically significant aGVHD in this cohort was low overall and the association was not statistically significant. (2) Since cytomegalovirus (CMV) reactivation and disease continued to be important complications post-HSCT, and CMV infection is of special concern in the Chinese population. The incidence of asymptomatic infection is high. The episodes of major infection were focused on early CMV infection post-HSCT. Early CMV infection refers to antigenemia or disease with onset by day 100 after transplantation. In the present study cohorts, all patients and almost all donors were CMV seropositive (CMV-specific immune globulin G positive, CMV-IgG(+)) before HSCT and only one donor from the Taiwan Tzu Chi Stem Cells Center was CMV seronegative. All patients received CMV prophylaxis treatment and those experiencing pre-transplantation CMV recurrent infection received preemptive treatment. Of the total of 240 patients, 134 (55.8%) had experienced early CMV infection with a median onset of 27 days (range 2–64) post-HSCT. Patients who received stem cells from donors with the TLR9 +1635 variant genotype (TT) had a reduced incidence of grades II–IV aGVHD, however, they experienced early CMV infection more frequently than those with the wild-type genotype (CT or TT) in both the URD transplantation cohort (TT: 80% vs. CT or CC: 59.3%, Gray's test p =0.02) and the sibling transplantation cohort (TT: 66.7% vs. CT or CC: 41.7%, Gray's test p=0.03), although a higher incidence of early CMV infection was observed in the URD transplantation cohort (63% vs. 46%, Gray's test p = 0.025). Multivariate analysis confirmed unrelated donors (p =0.046, RR = 1.438, 95%CI,1.007–2.053), patients experiencing recurrent CMV infection pre-transplantation (p = 0.004, RR = 0.597, 95%CI, 0.419–0.849) and donors with the TLR9 +1635 TT genotype (p=0.005, RR=0.561, 95%CI, 0.376–0.836) all contributed to the development of early CMV infection. Conclusion: There is increasing evidence for a role for TLR9 in the pathogenesis of aGVHD and viral infection. These result is the first report of donor TLR9 gene polymorphic features with the risk of aGVHD and early CMV infection, which are located within the promoter region and coding polymorphisms and may influence transcriptional regulation and the amino acid exchange of the TLR9 gene. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 3906-3906
    Abstract: In murine models, donor natural killer cells(NK) exhibit immunoregulatory functions to alloreactive T cells during the initiation of acute graft versus host disease(aGVHD). The immunoregulatory role of NK cells in human aGVHD remains unclear. Here we compared the regulation of alloreactive donor T cell response by donor CD56+NK cells in 63 patients receiving allogeneic hematopoietic stem cell transplantation(allo-HSCT) and their donors. We found that NK cells from donors effectively suppressed T cell proliferation in response to Allo-DCs, showing cytotoxicity against activated proliferating T cells but not resting T cells. Subgroup of NK cells influenced the cytotoxicity against allo-reactive T cells, NKG2A-CD57+ NK cells degranulated to activated auto-T cells more potently than NKG2A+CD57- subgroup, suggesting NKG2A and CD57 expression patterns influenced NK cytotoxicity against activated T cells. When we analyzed the alteration in potential ligands for NK activating receptors on CD3+T cells during stimulated by allo-antigens, we found that activated T cells expressed higher levels of NKG2D-L(MICA/B,ULBP-1/ 2/ 4), DNAM1-L(PVR), and LFA-L(ICAM-1 and ICAM-2). Using neutralizing antibodies to block the interaction between NK receptors and correspondence ligands, we found that both activating receptor(LFA-1,NKG2D and DNAM-1) and inhibited receptor(NKG2A and TIM-3) participated this process. In the first 3 months post HSCT, reconstituted NK cells were mainly CD56bright and NKG2A+ CD57- subgroup, and percent of CD11b+CD27+ subgroup was significantly higher than in health donors, indicating relative immature subgroup predominated the early reconstituted NK cells after transplantation. By evaluating the dynamic restitution regularity of NK cell receptoires after Allo-HSCT, we found that the early reconstituted NK cells had a notably decreased surface expression of DNAM-1 and NKG2D compared with their corresponding donors. Furthermore, we compared the expression of receptors on CD56+NK cells from patients who developed aGVHD (group GVHD) with those without aGVHD (group non-GVHD) at 4 weeks after transplantation. Interestingly, we found that decreased expression of DNAM-1 and NKG2D and enhanced NKG2A expression are associated with aGVHD. When we assessed the expression of ligands for activating NK-cell receptors on activated T cells in aGVHD and non-aGVHD patients, we found that T cells in aGVHD patients expressed higher level of PVR(ligand for DNAM-1) and MICA/B(ligand for NKG2D) when compared with no-aGVHD patients or donors. To explore whether the subgroup alteration and reduced activating receptors expression on NK cells in aGVHD patients affected their capacity of GVHD regulation, we next examined NK-cell degranulation and cytotoxicity to allogeneic antigen activated T cells. The results demonstrated that the ability of donor NK cells to inhibit and lyse autologous activated T cells is impaired during human GVHD. Of clinical relevance, the tyrosine kinase inhibitor(TKI) dasatinib enhanced NK cytotoxicity towards activated T cells by up-regulating the expression of CD226 and NKG2D and enhancing the proportion of CD57+NKG2A- subgroup. This study demonstrates for the first time that the ability of donor NK cells to inhibit alloreactive T cells response is impaired during human GVHD and dasatinib may reinforced the GVHD-regulation function of NK cells, which potentially may provide an opportunity for therapeutic treatment of GVHD. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 3338-3338
    Abstract: Introduction The order of alternative donor selection for hematopoietic stem cell transplantation (HSCT) for patients with hematologic malignancies has not been addressed. We performed the first prospective trial to compare the effect of HSCT from matched sibling donors (MSDs), unrelated donors (URDs) and haploidentical- related donors (HRDs) in a contemporary protocol. Methods From 2008 to 2012, 234 patients with hematologic malignancies were enrolled. The treatment schedule was as follows: if a fully MSD was available, patients were assigned treatment with MSD-HSCT. If an MSD was unavailable, a suitably matched URD was used as the alternative, where a suitable match involved matching more than 8 of 10 HLA-A, -B, -C, -DRB1and DQ allele loci ( ¡Ý 8/10) and at least 5 of 6 matching HLA-A, -B, and -DRB1 antigen loci. If only URDs with 〉 2 mismatching allele loci were available, patients were allowed treatment with HRD-HSCT. Results (1) Sixty-eight patients underwent MSD-HSCT, 98 patients underwent URD-HSCT, and 68 patients underwent HRD-HSCT (Table 1). (2) Grades II¨CIV and severe aGVHD were all significantly more frequent in patients undergoing HRD-HSCT compared with those undergoing MSD-HSCT (II¨CIV: 42.6% vs 19.1%, P = 0.0015; severe aGVHD: 17.65% vs 5.88%, P = 0.03). However, the incidences of II¨CIV and severe aGVHD were comparable in patients receiving transplants from HRDs to those from URDs (II¨CIV: 42.6% vs 40.8%, P = 0.89; severe aGVHD: 17.65% vs 13.27%, P = 0.48). The incidence of cGVHD was not significantly affected by donor types. (3) The 4-year incidence of relapse was not significantly affected by donor types according to all patients (24.2% in the MSD cohort, 22.8% in the URD cohort, 11.9% in the HRD cohort, P 〉 0.05). However, after controlling for high-risk patients, a superior graft-versus-leukemia (GVL) effect was observed in patients undergoing HRD-HSCT compared to MSD-HSCT or URD-HSCT. In high-risk patients receiving MSD, 36.8% experienced relapse, as did 33.6% in the URD cohort, but the incidence decreased to11.1% in the HRD cohort (MSD vs HRD, P = 0.015; URD vs HRD, P = 0 .028). (4) HRD-HSCT yielded comparable rates of 4-year overall survival (OS) and disease-free survival (DFS) to MSD-HSCT ( OS: 66.4% vs 79.5%, P = 0.071; DFS: 66.4% vs 78.2 %, P = 0.109) or URD-HSCT (OS: 66.4% vs 59%, P = 0.952; DFS: 66.4% vs 58.1%, P = 0.864) (Figure 1). Conclusion Our data provide convincing clinical evidence to support the use of HRDs, as well as URDs, can be selected as first-line alternative donors, especially for high-risk patients. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 124, No. 17 ( 2014-10-23), p. 2735-2743
    Abstract: We developed an approach of T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin. Outcomes of suitably matched URD-HSCT and HRD-HSCT are similar, and HRD-HSCT improves outcomes of patients with high-risk leukemia.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Molecular Pharmaceutics, American Chemical Society (ACS), Vol. 10, No. 9 ( 2013-09-03), p. 3447-3458
    Type of Medium: Online Resource
    ISSN: 1543-8384 , 1543-8392
    Language: English
    Publisher: American Chemical Society (ACS)
    Publication Date: 2013
    detail.hit.zdb_id: 2132489-X
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    Elsevier BV ; 2014
    In:  Microbiological Research Vol. 169, No. 9-10 ( 2014-09), p. 759-767
    In: Microbiological Research, Elsevier BV, Vol. 169, No. 9-10 ( 2014-09), p. 759-767
    Type of Medium: Online Resource
    ISSN: 0944-5013
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2014
    detail.hit.zdb_id: 2051526-1
    detail.hit.zdb_id: 1189614-0
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 2377-2377
    Abstract: Abstract 2377 Background: Mycophenolate mofetil (MMF) has been widely used in the prophylaxis and treatment of graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Inosine monophosphate dehydrogenase (IMPDH) is the target of mycophenolic acid (MPA), the active metabolite of MMF. IMPDH is the key enzyme in the de-novo synthesis of nucleotides and induces the rate-limiting step in this synthesis. There are two isoforms of IMPDH, IMPDH1 is constructively expressed in all cell types, whereas IMPDH2 is only expressed in particular cell types. The proliferation of lymphocytes depends on the synthesis of nucleotides by IMPDH, whereas other types of cells have a salvage pathway for the synthesis of nucleotides. This makes MPA a drug that specifically inhibits the proliferation of the lymphocytes. Interindividual variability in IMPDH activity has been observed in healthy volunteers as well as transplant patients. The considerable variability in baseline IMPDH activity and MPA response may logically be under the control of genetic variation within the IMPDH gene or in gene expression. Analysis of genetic variants could provide the explantation for the variability of IMPDH activity and MMF response in transplant patients. The single nucleotide polymorphism (SNP) of IMPDH1 gene has recently reported to be relevant to acute rejection in renal transplant patients receiving MMF. There are no data about the impact of the polymorphisms of IMPDH1 gene on the outcome of allo-HSCT. The objective of this study was to investigate IMPDH1 genetic variants in allo-HSCT patients and to retrospectively look for the association of these polymorphisms with aGVHD. Methods: The entire study population consisted of 240 consecutive pairs of transplant recipients and their donors who were transplanted from 2001 to 2009 in our Center, including 138 pairs of recipients and their unrelated donors and 102 pairs of recipients and their HLA-identical sibling donors. Both in the unrelated and sibling transplantation cohorts, the patients received the same GVHD prophylaxis consisting of cyclosporin A, a short-term methotrexate and MMF. Genomic DNA was extracted from peripheral blood samples obtained from recipients and donors before transplantation. Four SNPs of IVS7 +125 G 〉 A (rs2278293), IVS8-106 G 〉 A (rs2278294), Exon15 1572 G 〉 A (rs2228075) and 5` flanking region C 〉 T (rs714510) in IMPDH1 gene were analyzed by Multiplex SnaPshot. Results: (1) The IMPDH1 IVS8 -106 G/G genotypes in recipients were significantly associated with a higher incidence of aGVHD than recipients with other genotypes either in the unrelated transplantation cohort or in the sibling transplantation cohort (in the unrelated cohort: 83.3% vs 63.9%, P=0.048; in the sibling cohort: 47.6% vs17.3%, P=0.008). Furthermore, in the unrelated transplantation cohort, the IMPDH1 IVS8 -106 G/G genotypes in recipients were also associated with a higher incidence of grades II-IV aGVHD (63.3% vs 38.0%, P=0.021). However donor IMPDH1 IVS8 -106 genotype had no significant influence on the incidence of aGVHD. (2) In the combined cohort, multivariate analysis confirmed that recipients with the IVS8 -106 G/G genotype were significantly associated with higher risk of developing aGVHD (RR=2.018, 95%CI: 1.354–3.009, P=0.001). Other three variables associated with the risk of aGVHD were myeloablative conditioning (RR=3.309, 95%CI: 1.538–7.121, P=0.002), donor female and recipient male (RR=1.679, 95%CI: 1.139–2.475, P=0.009), and unrelated donor (RR=4.633, 95%CI: 2.934–7.315, P 〈 0.001). (3) The genotypes of IVS7 +125, Exon15 1572 and 5` flanking region were not found to be associated with the risk of aGVHD. Conclusions: These results, which is the first report of IMPDH1 gene polymorphic features of Chinese population with the risk of aGVHD, suggest an interaction of the recipient IMPDH1 IVS8 -106 genotypes on the risk of aGVHD. These results are helpful for predicting allo-HSCT outcome, monitoring MMF therapy on an individual patient basis. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2010
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Biology of Blood and Marrow Transplantation, Elsevier BV, Vol. 17, No. 4 ( 2011-04), p. 542-549
    Type of Medium: Online Resource
    ISSN: 1083-8791
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2011
    detail.hit.zdb_id: 3056525-X
    detail.hit.zdb_id: 2057605-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...